These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24685542)

  • 21. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
    Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
    Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.
    Zhao X; Xin M; Huang W; Ren Y; Jin Q; Tang F; Jiang H; Wang Y; Yang J; Mo S; Xiang H
    Bioorg Med Chem; 2015 Jan; 23(2):348-64. PubMed ID: 25515957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
    Mera WA; Alzihlif M; Taha MO; Khanfar MA
    Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
    Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
    Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis.
    Lou Y; Han X; Kuglstatter A; Kondru RK; Sweeney ZK; Soth M; McIntosh J; Litman R; Suh J; Kocer B; Davis D; Park J; Frauchiger S; Dewdney N; Zecic H; Taygerly JP; Sarma K; Hong J; Hill RJ; Gabriel T; Goldstein DM; Owens TD
    J Med Chem; 2015 Jan; 58(1):512-6. PubMed ID: 24712864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
    Kawahata W; Asami T; Fujii I; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
    Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
    Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.
    Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Eigenbrot C; Gallion S; Johnson AR; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Wang X; Wong H; Xiong JM; Xu J; Yu C; Zhao Z; Currie KS
    Bioorg Med Chem Lett; 2016 Jan; 26(2):575-579. PubMed ID: 26675441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
    Ysebaert L; Michallet AS
    Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
    Li X; Zuo Y; Tang G; Wang Y; Zhou Y; Wang X; Guo T; Xia M; Ding N; Pan Z
    J Med Chem; 2014 Jun; 57(12):5112-28. PubMed ID: 24915291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
    Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.